New investigational drug for treatment of platinum-resistant ovarian cancer

Trial ID:
IRB-25-8649
Jo Marie Tran Janco, MD

Inclusion Criteria

Patients must:

  • Be female and aged 18 years or older
    Have a histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Have received platinum-based therapy
    Have received 1 to 4 lines of prior systemic therapy

Exclusion Criteria

Patients must not:

  • Be pregnant, breastfeeding, or have the intention of becoming pregnant during the study
    Have endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of these histologies, or low-grade/borderline ovarian cancer
    Have active CNS metastases and/or carcinomatous meningitis
    Have clinically significant or uncontrolled cardiac disease within 6 months before study treatment

Additional Info

All treatments and physician visits during this study will take place at Scripps Prebys Cancer Center in Hillcrest.

For more information, search NCT07023627 at https://clinicaltrials.gov/

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org